Corporate Snapshot: Cspc Hunan Jingfeng Pharmaceutical
Cspc Hunan Jingfeng Pharmaceutical (000908.SZ) closed the trading day on Monday, 26 November 2026, unchanged, at a flat 0 % relative to the previous close. The last recorded price on major exchanges was CNY 5.16 per share. With a circulating supply of approximately 1.8 billion shares, the company’s market capitalisation stands at CNY 9.4 billion. In the past 24 hours, trading volume amounted to roughly CNY 82.7 million, a modest figure that reflects a relatively quiet session.
Recent Performance and Technical Indicators
- 24‑hour performance: -11.57 % decline since the end of last month, indicating a broader trend of downside pressure.
- Simple Moving Average (200 days): CNY 6.36, suggesting that the current price lies well below the long‑term average.
- 52‑week range: The highest price reached CNY 9.48 on 17 November 2025, while the low fell to CNY 4.58 on 11 March 2026, indicating a recent narrowing of the range but still a significant swing over the year.
Comparative Peer Activity
The following table summarises how a selection of peers performed in the same 24‑hour window:
| Stock | Symbol | 24‑hour change | Current price | Market Cap (CNY bn) | P/E Ratio |
|---|---|---|---|---|---|
| Xiamen Kingdomway | 002626.SZ | 0 % | CNY 18.42 | 11.3 | 44.81 |
| Guangdong Baolihua New | 000690.SZ | 0 % | CNY 5.26 | 11.3 | 10.36 |
| Wuxi Xinhongye Wire & Cable | 301310.SZ | 0 % | CNY 55.58 | 11.3 | – |
| Zhejiang Medicine | 600216.SS | 0 % | CNY 12.02 | 11.3 | 14.12 |
| Beijing Aosaikang Pharm | 002755.SZ | 0 % | CNY 12.28 | 11.2 | 151.8 |
All listed peers showed a flat 0 % change in the same period, underscoring a broader market stagnation across the healthcare and consumer sectors.
Sector Context
Analysts have highlighted a recent rally in China’s food and beverage sector, driven by consumer spending momentum and supportive policy initiatives from the Ministry of Commerce. The focus on artificial‑intelligence‑enabled consumption, rural market expansion, and smart‑home purchases is reshaping the domestic demand landscape. While the sector’s valuation remains attractive, the shift toward lower‑valued, stable‑cash‑flow companies signals a tightening risk appetite that has drawn capital away from higher‑growth, more volatile stocks.
Company Overview
Hunan Jingfeng Pharmaceutical Co., Ltd., headquartered in Shanghai, specialises in the development and sale of a broad portfolio of pharmaceutical products, including chemical medicines, biologics, traditional Chinese medicine, and related products. The company has been listed on the Shenzhen Stock Exchange since 1998 and maintains a commercial presence across China. Further information can be found on its website at www.jfyiyao.com .
This article synthesises publicly available market data and analyst commentary to provide an overview of Cspc Hunan Jingfeng Pharmaceutical’s recent performance and its positioning within the broader healthcare and consumer sectors.